DDDimo Dimov

Dimo Dimov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dimo Dimov has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Serum MMP-8 and promotor MMP-8 -799 G>A SNP as possible markers of non-eosinophilic bronchial asthma

    by Dimo Dimov, Elina Aleksandrova, Tanya Tacheva, Hristina Petrova, Tatyana Vlaykova

    Bronchial asthma is a complex heterogenous chronic inflammatory lung disease that presents with several clinical phenotypes with a distinct pathobiology and biomarkers. In the current preliminary study, we aimed to evaluate the possible role of MMP-8 and MMP-8 -799 G>A (rs11225395) promoter polymorphism as biomarkers in bronchial asthma. The genotyping of patients’ and control groups was performed by PCR-RFLP method and the serum level was assessed by ELISA method. The AA genotype was with marginal significance more common among controls (0.289) than in patients (0.129) when compared to the wild type G allele genotypes (GG+GA, p=0.040). A higher serum levels of MMP-8 was found in asthma patients (5.45±0.62 (SEM) ng/ml) than to control individuals (2.71±0.52 ng/ml, p=0.010). No significant difference was seen in serum MMP-8 neither in controls or in patients with different MMP8 genotype (p=0.556 and p=0.465). Serum MMP-8 correlated negatively with blood eosinophils (Rho= -0.531, pA SNP might be protective both for development and progression of bronchial asthma. Funding: University Project 3/2023, Trakia University and Project No. BG-RRP-2.004-0006-C02.

  • Evaluation of the serum AGEs, cLDL and LOX-1 as biomarkers in COPD.

    by Dimo Dimov, Tanya Tacheva, Elina Aleksandrova, Hristina Petrova, Tatyana Vlaykova

    In the current study we aimed to evaluate the possible role in COPD of three serum markers of oxidative stress and modification of proteins and lipoproteins: Advanced glycation end products (AGEs), Carbamylated LDL (cLDL) and Soluble lectin-like oxidized LDL receptor-1 (LOX-1). Only the levels of AGEs were significantly higher in COPD patients than in controls (p=0.001), while cLDL and LOX-1 did dot differed significantly (p=0.349 and p=0.7592). However, cLDL and LOX-1, but not AGEs, were significantly higher in patients with current and ex-smoking history than non-smokers (p=0.006 and p=0.050), and correlated significantly with the length of the disease (Rho=0.422, p=0.008 and Rho=0.394, p=0.014). The cLDL and LOX-1 showed also significant negative correlations with the FEV1 % pr. and FEV1/FVC %: Rho= -0.421, p=0.006 and Rho= -0.548, p<0.0001 for cLDL; Rho= -0.339, p=0.030 and Rho= -0.379, p=0.015 for LOX-1. Moreover, cLDL and LOX-1 were significantly higher in patients GOLD III/IV than with GOLD II COPD (p<0.0001 for cLDL; p=0.006 for LOX-1) and cLDL was also significantly higher in patients with 2 or more exacerbations during the last year (p=0.018). Patients with Arterial Hypertension (AH) had significantly higher AGEs (p=0.015) and higher, but not significantly cLDL (p=0.086) and LOX-1 (p=0.180). AGEs correlated with two new markers for inflammatory disease progression: PLR (Rho=- 0.457, p=0.043) and LMR (Rho=0.482, p=0.040). The results suggest that serum cLDL and LOX-1 might be considered as biomarkers for decline of lung function, while the serum AGEs might be a factor in pathogenesis of AH in in COPD. Funding: Project 3/2023, Trakia University and Project No. BG-RRP-2.004-0006-C02

  • Serum markers of bone metabolism correlate with clinical parameters for disease progression during 2 years follow-up in patients with COPD

    by Dimo Dimov, Tanya Tacheva, Yanitsa Zhelyazkova, Tatyana Vlaykova

    The aim of the study was to explore the possible role of three serum markers of bone metabolism, 25-hydroxyvitamin D [25(OH)D], osteoprotegerin (OPG) and osteopontin (OPN) as indicators of COPD progression. We assessed the serum levels in 58 patients with COPD followed for 2 years and in 23 control individuals. All studied serum markers were significantly lower in COPD patients in comparison to controls (p<0.0001). Serum OPN was significantly lower in patients with early GOLD stages (stage 1 and 2) than in advanced (stage 3 and 4) (p=0.035) and had weak negative correlation with FEV1% at the beginning (p=0.054) and at the end of the follow-up period (p=0.028). On opposite, serum OPG tended to be higher in patients with early stages and to correlate positively with FEV1/FVC% at the beginning and with FEV1% in the end of the study period. OPG was significantly higher in patients which during the follow-up period did not worsen their lung function than those which had decrease in FEV1% (p=0.045) and decreased FEV1/FVC% (p=0.034). Moreover, OPG correlated negatively with the CAT scores in the beginning of the study period (p=0.016) and with the number of the hospitalization (p=0.025). The serum 25(OH)D negatively correlated with the number of exacerbations during the study period (p=0.055) and had significant positive correlations with FEV1% (Rho=0.728, p=0.003) and FVC% (Rho=0.638, p=0.014) but only in patients with advance stages. The results suggest that the higher serum OPG and vitamin D might be markers for improving the COPD patient conditions and lung function, while the serum OPN might determine worsening.

  • Open Access

    The Serum Levels of the Heavy Metals Cu, Zn, Cd, and Pb and Progression of COPD—A Preliminary Study

    by Elica Valkova, Vasil Atanasov, Tatyana Vlaykova, Tanya Tacheva, Yanitsa Zhelyazkova, Dimo Dimov, Kristian Yakimov

    There is evidence in previous studies that high levels of heavy metals may play a key role in the development of COPD due to the induction of chronic inflammation and oxidative stress. In this preliminary study, we used atomic absorption spectrophotometry to measure the levels of four heavy metals (Cu, Zn, Cd, and Pb) in blood serum of COPD patients and controls over 2 years. Clinical data on disease progression or absence were collected in patients living in the industrial region of Stara Zagora, Bulgaria. The mean values of Cu in the serum of patients with COPD and the control group were 374.29 ± 15.03 μg/L and 238.55 ± 175.31 μg/L, Zn—2010.435 ± 670.006 μg/L and 1672.78 ± 934.27 μg/L, Cd—0.334 ± 0.0216 μg/L and 0.395 ± 0.110 μg/L and Pb—0.0732 ± 0.009 μg/L and 0.075 ± 0.0153 μg/L. This is probably because these elements are biogenic and are used in the body for its anti-oxidant protection. In fact, it cannot be stated with certainty that elevated levels of Cu and Zn in the environment have a negative impact in COPD patients. There was a trend towards higher levels of the toxicants lead and cadmium in COPD patients compared to the control group of patients. There is a statistically unproven trend toward higher levels of lead and cadmium in COPD patients compared to controls, which to some extent supports our hypothesis that there is a relationship between environmental lead and cadmium levels and the COPD manifested. In COPD patients, a positive correlation was found between BMI and serum Cu levels (r = 0.413, p = 0.005). A higher concentration of serum Cu was found in men with BMI ≥ 30, compared to those with BMI < 30. There is also a positive correlation to a lesser extent between CRP and cadmium (r = 0.380; p = 0.019) and lead (r = 0.452; p = 0.004). The correlation of lead and cadmium with PSA also shows that these elements may also be associated with the presence of inflammatory processes. A significant negative correlation exists between Pb in the serum of patients with COPD and their blood hemoglobin (r = −356; p = 0.028). The results of our study suggest that higher doses of the trace elements Cu and Zn do not always have a negative effect in patients with COPD, while the toxicants Pb and Cd may be involved in COPD exacerbation and can be used as prognostic biomarkers for progression. Further studies are warranted to confirm these preliminary results.


  • Open Access

    Possible Role of Serum Leptin as Biomarker in COPD

    by Yanitsa A. Zhelyazkova, Tanya T. Tacheva, Dimo M. Dimov, Denitsa G. Vlaykova, Aneliya V. Bivolarska, Tatyana I. Vlaykova

    Leptin is one of the adipokines shown to exert a significant effect in respiratory diseases, including chronic obstructive pulmonary disease (COPD).The aim of the present study was to evaluate the possible role of serum leptin as biomarker in COPD.The serum leptin levels were assessed in 58 patents with stable COPD and 21 controls applying ELISA method.The leptin levels were higher, although not significantly, in COPD patients than in controls (221.52±24.28(SE) vs. 165.04±26.01 pg/ml, p=0.197). This tendency turned out significant when only females were compared (414.60±60.63 vs. 219.40±44.15 pg/ml, p=0.038). The levels of leptin were highly dependent on the BMI both in COPD patients (pp=0.024): they were the highest in obese individuals and decreased with reducing the BMI.In the COPD group, women had significantly higher leptin levels than men (pp=0.007) and current smokers (p=0.007). In patients with BMI above 25, several associations were observed: patients with mild COPD had higher serum leptin level than those with severe or very severe COPD (p=0.038); the leptin levels correlated positively with FEV1% (r= 0.304, p=0.045) and FEV1/FVC ratio (I= 0.348, p=0.021), and tended to correlate negatively with ABCD GOLD groups (Rho=-0.300, p=0.043) and with the CAT points (Rho=-0.258, p=0.091); the leptin levels below 300 ng/ml determined 4.08-fold higher risk for more severe COPD.The results of our study confirm that the serum leptin levels depend significantly on the BMI and are interfered by gender and smoking habits. However, this adipokine cannot be used as a serum biomarker for distinguishing COPD patients, but its decrease might be associated with aggravation of the disease.


  • Open Access

    Gender differences of the anthropometric indices of abdominal obesity in individuals with COPD

    by Maya Gulubova, Dimo Dimov, Koni Ivanova, Atanas Atanasov, Tanya Tacheva, Tatyana Vlaykova

    COPD is a chronic inflammatory lung disease which is associated with variety of co-morbidities, as the obesity and cardiovascular diseases (CVDs) are the most frequent. The aim of the current study was to explore the correlations of the age and BMI with the anthropometric indices associated with abdominal obesity in individuals with COPD and to explore the possible difference between the genders. Material and methods: This cross-sectional analysis included 851 citizens from the region of Yambol, Bulgaria. They were interviewed and blood pressure was measured during events organized at the World Diabetes Day, November 14, 2016-2018. One hundred and three of the individuals reported previous diagnosis of COPD. The further statistical analyses were performed only in this group of individuals applying SPSS 16.0 for Windows (SPSS Inc.). Results: Thirty three (32%) of the individuals with COPD were men with a mean age of 58.12 ±13.76 years, while the rest of 70 (68%) persons were women with a mean age of 66.70±10.73 years (p=0.001). The body mass index (BMI) correlated positively with the anthropometric indices associated with central obesity: the waist circumferences (WC, r=0.601, p<0.0001), the hip circumferences (HC, r=0.619, p<0.0001) and waist-to-hip ratio (WHR, r=0.214, p=0.033). The age correlated positively only with the WHR ratio in men (r=0.390, p=0.025), but not in women. When comparing the BMI between genders we did not observed difference (p=0.802). However when classified into groups according to the BMI, women were more frequently with normal weight (30.4%) and obese (33.3%) compared to men (25.8% and 16.1%, respectively), while men were more often with overweight than women (58.1% vs. 36.2%, p=0.091). Men had higher WC (99.23±11.40 cm, p=0.080) and especially WHR (0.922±0.067, p<0.0001) than women (94.17±14.50 cm and 0.855±0.084, respectively). According to the WHR the abdominal obesity was more frequently observed in men with COPD (78.8%) than in COPD women (58.6%. p=0.045). The measured high blood pressure was significantly associated with central obesity both in women (p=0.038) and in men (p=0.035). Conclusions: The results of our study confirm the positive correlation of the BMI with other anthropometric indices associated with abdominal obesity. Based on the results we could conclude that central obesity is more common in men than in women and determines a risk for higher blood pressure in patients with COPD.

  • Visfatin as a possible serum biomarker in COPD

    by Dimo Dimov, Tanya Tacheva, Yanitsa Zhelyazkova, Niamh O’dOnoghue, Denits Vlaykova, Tatyana Vlaykova

    COPD is a chronic disease, characterized by persistent airflow limitation and systemic manifestations. It is suggested that the adipose tissue may play a critical role in promoting systemic inflammation in COPD possibly by secretion of adipokines (including visfatin). Visfatin (visceral fat-derived hormone) is a pro-inflammatory cytokine which acts on early B-lineage precursor cells. It has also an enzyme activity (nicotinamide phosphoribosyltransferase): the rate-limiting enzyme in salvage pathway of NAD. The aim of our study was to evaluate the role of visfatin as possible biomarker in COPD. We assessed the serum levels of visfatin in 58 patents with COPD and 22controls by commercial ELISA kit. COPD patients had significantly higher visfatin levels compared to controls (181.04±13.82pg/ml vs. 74.4±14.13pg/ml, p<0.0001). In the group of patients the current smokers had significantly higher visfatin compared to non- or ex-smokers (p= 0.013), and the overweight patients had elevated concentrations than patients with normal BMI (219.46±20.86pg/ml vs. 147.80±29.49pg/ml, p=0.041). Serum leptin was significantly higher in patients with stages GOLD III and IV than those stages GOLD I and II (221.3±17.85pg/ml vs. 159.86±18.11pg/ml, p=0.033); it tended to be higher in patients of group D compare to those of A and B (GOLD 2017) (p=0.078); and it positively correlated with the CAT test points (r=0.227, p=0.035). According to our results visfatin is affected by smoking habits and might be used as biomarker for more advanced and symptomatic COPD. This work was performed with the support of SUP 3/2017 and project 3/2018, Medical Faculty, Trakia University, Stara Zagora, Bulgaria.


  • Open Access

    A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

    by Jeffrey M. Harris, Romeo Maciuca, Mary S. Bradley, Christopher R. Cabanski, Heleen Scheerens, Jeremy Lim, Fang Cai, Mona Kishnani, X. Charlene Liao, Divya Samineni, et al.

    Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. In patients with mild asthma, quilizumab reduced serum IgE and attenuated the early and late asthmatic reaction following whole lung allergen challenge. This study evaluated the efficacy and safety of quilizumab in adults with allergic asthma, inadequately controlled despite high-dose inhaled corticosteroids (ICS) and a second controller. Five hundred seventy-eight patients were randomized to monthly or quarterly dosing regimens of subcutaneous quilizumab or placebo for 36 weeks, with a 48-week safety follow-up. Quilizumab was evaluated for effects on the rate of asthma exacerbations, lung function, patient symptoms, serum IgE, and pharmacokinetics. Exploratory analyses were conducted on biomarker subgroups (periostin, blood eosinophils, serum IgE, and exhaled nitric oxide). Quilizumab was well tolerated and reduced serum total and allergen-specific IgE by 30–40 %, but had no impact on asthma exacerbations, lung function, or patient-reported symptom measures. At Week 36, the 300 mg monthly quilizumab group showed a 19.6 % reduction (p = 0.38) in the asthma exacerbation rate relative to placebo, but this was neither statistically nor clinically significant. Biomarker subgroups did not reveal meaningful efficacy benefits following quilizumab treatment. Quilizumab had an acceptable safety profile and reduced serum IgE. However, targeting the IgE pathway via depletion of IgE-switched and memory B cells was not sufficient for a clinically meaningful benefit for adults with allergic asthma uncontrolled by standard therapy. ClinicalTrials.gov NCT01582503